BSPRY

Across TCGA pan-cancer cohorts, BSPRY mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of BSPRY’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where BSPRY mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types BSPRY is over-expressed in tumor, although a few such as CCRCC and LSCC show the opposite, repressed pattern.

CCRCC, LSCC, and HNSC are the cancer types where BSPRY tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BSPRY mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	IV	−1.330	<.001	12	view →
LSCC	Female	All	−0.771	<.001	9	view →
HNSC	Male	All	−0.708	<.001	9	view →
COAD	All	All	+0.271	<.001	9	view →
LUAD	Female	All	+0.545	<.001	6	view →
PDAC	Female	All	−0.681	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

BSPRY–CCRCC

Open the CCRCC breakdown →